Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Incyte Corporation
  6. Summary
    INCY   US45337C1027

INCYTE CORPORATION

(INCY)
  Report
Delayed Nasdaq  -  04:00 2022-09-29 pm EDT
66.61 USD   -1.55%
09/29MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi (tafasitamab-cxix) for Patients with R/R DLBCL
AQ
09/12Transcript : Incyte Corporation Presents at Morgan Stanley 20th Annual Global Healthcare Conference, Sep-12-2022 12:30 PM
CI
09/02RBC Capital Cuts Incyte's Price Target to $78 From $82, Keeps Outperform Rating
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/23/2022 09/26/2022 09/27/2022 09/28/2022 09/29/2022 Date
66.89(c) 66.18(c) 66.44(c) 67.66(c) 66.61(c) Last
1 311 579 1 115 084 1 818 937 1 559 237 1 265 247 Volume
-0.77% -1.06% +0.39% +1.84% -1.55% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 3 382 M - -
Net income 2022 471 M - -
Net cash position 2022 2 643 M - -
P/E ratio 2022 32,0x
Yield 2022 -
Sales 2023 3 908 M - -
Net income 2023 777 M - -
Net cash position 2023 3 256 M - -
P/E ratio 2023 19,3x
Yield 2023 -
Capitalization 14 816 M 14 816 M -
EV / Sales 2022 3,60x
EV / Sales 2023 2,96x
Nbr of Employees 2 094
Free-Float 98,4%
More Financials
Company
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (77.7%); - royalties (19.1%); - income from research and cooperation agreements (3.2%). 
Sector
Pharmaceuticals
Calendar
11/01Earnings Release
More about the company
Ratings of Incyte Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about INCYTE CORPORATION
09/29MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatm..
AQ
09/12Transcript : Incyte Corporation Presents at Morgan Stanley 20th Annual Global..
CI
09/02RBC Capital Cuts Incyte's Price Target to $78 From $82, Keeps Outperform Rating
MT
08/26Incyte Secures FDA Approval For Pemazyre As Treatment For Myeloid/Lymphoid Neoplasms
MT
08/26Incyte Announces FDA Approval of Pemazyre® (pemigatinib) as the First and Only Targeted..
BU
08/26Incyte Corporation Announces FDA Approval Of Pemazyre® (Pemigatinib) As The First And O..
CI
08/26Incyte Gets FDA Approval for Rare-Blood-Cancer Treatment
DJ
08/24Data from Incyte's Dermatology Portfolio Accepted for Presentation at the 2022 European..
BU
08/23Incyte to Present at Upcoming Investor Conference
BU
08/04North American Morning Briefing: Stock Futures -3-
DJ
08/03Evercore ISI Downgrades Incyte to In Line From Outperform, Lowers Price Target to $78 F..
MT
08/03Morgan Stanley Adjusts Incyte's Price Target to $76 From $77, Keeps Equalweight Rating
MT
08/03Oppenheimer Adjusts Incyte's Price Target to $98 From $109, Maintains Outperform Rating
MT
08/03Guggenheim Downgrades Incyte to Neutral From Buy
MT
08/02INCYTE CORP Management's Discussion and Analysis of Financial Condition and Results of..
AQ
More news
News in other languages on INCYTE CORPORATION
08/27Incyte annonce que le Pemazyre ® (pemigatinib) a été approuvé par la FDA en tant que pr..
08/27Incyte gibt FDA-Zulassung von Pemazyre® (Pemigatinib) als erste und einzige zielgericht..
08/26Incyte obtient l'approbation de la FDA pour le Pemazyre comme traitement des néoplasmes..
08/26Incyte Corporation annonce l'approbation par la FDA de Pemazyre® (Pemigatinib) comme pr..
08/25Daten aus dem Dermatologie-Portfolio von Incyte zur Präsentation auf dem Kongress der E..
More news
Analyst Recommendations on INCYTE CORPORATION
More recommendations
ETFs positioned on INCYTE CORPORATIONETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
ASYMshares ASYMmetric 500 ETF - USD6.28%0.15%-NC
Invesco Dynamic Biotechnology & Genome ETF - USD4.83%2.97%United_States
Innovator IBD® Breakout Opportunities ETF - USD3.69%-4.21%World
VanEck Vectors Biotech ETF - USD3.57%0.94%United_States
First Trust NYSE Arca Biotechnology - Acc - USD3.48%-0.20%-United_States
More ETFs positioned on INCYTE CORPORATION
Chart INCYTE CORPORATION
Duration : Period :
Incyte Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INCYTE CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 66,61 $
Average target price 88,47 $
Spread / Average Target 32,8%
EPS Revisions
Managers and Directors
Herve Hoppenot Chairman, President & Chief Executive Officer
Christiana Stamoulis Chief Financial Officer & Executive Vice President
Steven H. Stein Chief Medical Officer & Executive Vice President
Dashyant Dhanak Chief Scientific Officer & Executive VP
Julian Charles Baker Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
INCYTE CORPORATION-9.25%14 816
JOHNSON & JOHNSON-3.82%432 579
ELI LILLY AND COMPANY21.06%313 567
ROCHE HOLDING AG-15.52%269 089
ABBVIE INC.5.41%252 343
PFIZER, INC.-25.22%247 841